Scott Summers
Has grant
Co-Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Targeting a Ceramide Double Bond to Treat Cardiometabolic Disorders
Open Date: 2019-07-15
Close Date: 2023-04-30
Grant: Close
FASEB SRC on Regulation of Glucose Metabolism: From Cell Biology to Systems Physiology
Open Date: 2019-06-01
Close Date: 2020-05-31
Grant: Close
The Role of Ceramides in Skeletal Muscle
Open Date: 2018-01-01
Close Date: 2021-12-31
Grant: Close
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases
Open Date: 2017-09-15
Close Date: 2020-08-31
Grant: Close
Lipid Mediators of Insulin Resistance
Open Date: 2008-07-01
Close Date: 2013-10-30
Articles (25)
Year:
2026
Year:
2026
Metabolic-associated steatohepatitis (MASH) involves hepatocyte damage that cannot be explained solely by lipid accumulation. Here, to discover injury-specific pathways, we focused on a gene of uncertain function, EF-Hand Domain Family Member D1 (EFHD1), identified in human genome-wide association studies of liver injury but not liver fat. We show that EFHD1, a Ca 2+ -dependent actin crosslinker, stabilizes endoplasmic reticulum–mitochondria contact sites (ERMCS), detecting spatiotemporal coincidence of inter-organellar proximity and ER Ca 2+ release. During MASH, EFHD1 upregulation drives pathological mitochondrial fragmentation via excessive contact persistence. This structural failure promotes mitochondrial double-stranded RNA escape and activation of a maladaptive antiviral PKR-dependent stress response, a causal relationship also supported by Mendelian randomization in humans. Consequently, inhibiting EFHD1 in human and mouse models blunts hepatocyte damage. These findings identify EFHD1 as a Ca 2+ -dependent ERMCS stabilizer, reveal a hepatocyte-intrinsic injury pathway, and suggest EFHD1 inhibition as a therapeutic strategy.
Year:
2026
Gestational diabetes mellitus (GDM), a transient form of diabetes that resolves postpartum, is a major risk factor for type 2 diabetes (T2D) in women. While the progression from GDM to T2D is not fully understood, it involves both genetic and environmental components. By integrating clinical, metabolomic, and genome-wide association study (GWAS) data, we identified associations between decreased sphingolipid biosynthesis and future T2D, in part through the rs267738 allele of the CERS2 gene in Hispanic women shortly after a GDM pregnancy. To understand the impact of the CERS2 gene and risk allele on glucose regulation, we examined whole-body Cers2 knockout and rs267738 knock-in mice. Both models exhibited glucose intolerance and impaired insulin secretion in vivo. Islets isolated from these models also demonstrated reduced β cell function, as shown by decreased insulin secretion ex vivo. Overall, reduced circulating sphingolipids may indicate a high risk of GDM-to-T2D progression and reflect deficits in CERS2 activity that negatively affect glucose homeostasis and β cell function.
Year:
2025
Obesity is a global menace that has impacted more than 14% of adults worldwide and more than a third of Americans. Importantly, obesity is associated with an increased risk of more than 13 types of cancer and worse outcomes, including increased mortality. This review focuses on the importance of considering obesity and metabolic dysfunction in cancer risk as part of the NCI’s funded consortium known as the Metabolic Dysfunction and Cancer Risk Program. It describes previous and ongoing mouse models used in studies conducted by Metabolic Dysfunction and Cancer Risk Program consortium members, as well as other relevant studies. Most cancer studies examine tumor progression, metastasis, or recurrence, which are consequences following tumor onset; however, this approach does not consider risk per se. To truly model cancer risk, parameters to measure include the quantification of cancer onset, measured as incidence or latency. Investigators must be cognizant of many factors in study design, including the choice of cancer model and genetic strain. Preclinical approaches addressing risk typically include genetically engineered mouse models or the administration of irritants or carcinogens. We also discuss the transplantation of cells or tumors such as allografts or xenografts, with a focus on tumor rejection or regression to approximate cancer risk, not cancer progression. Herein, we highlight two cancers, breast and colorectal cancers, in which risk is associated with obesity and discussed varied murine model approaches, as well as key findings that explore cancer risk, prevention, or interception.
Year:
2025
Supplemental Table 3 provides effect estimates for the association of incident diabetes and all-cause mortality among obesity-related cancer survivors and cancer-free individuals, stratified by covariates that did not meet PH assumptions.
Year:
2025
Supplemental Table 6 provides effect estimates for the association of incident diabetes and cancer-specific mortality among obesity-related cancer survivors, stratified my covariates that did not meet PH assumptions.
Year:
2025
Supplemental Table 1. Criteria for metabolic phenotype classification. HDL high density lipoprotein cholesterol; HOMA-IR Homeostatic Model Assessment for Insulin Resistance ; hs-CRP high sensitive C-reactive protein
Year:
2025
Supplemental Figure 7. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.
Year:
2025
Supplemental Figure 5. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by ATP III criteria with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (36)
Shama Karanth
Assistant Professor
University of Florida
Marc Gunter
International Agency for Research on Cancer
Md Saifur Rahman Khan
Director, Bioinformatics and Metabolomics Unit, The Center for Immunometabolism
University of Pittsburgh
Garnet Anderson
Fred Hutchinson Cancer Research Center
Babak Razani
Chief of Cardiology
VA Pittsburgh Healthcare System
Sihem Boudina
University of Utah
Aladdin Shadyab
Associate Professor
University of California, San Diego
Vivek Garg
Assistant Professor
University of Maryland
Fred Tabung
University of South Carolina
Julie Van
University of Toronto
Marian Neuhouser
Professor
Fred Hutchinson Cancer Research Center
Enrique Balderas-Angeles
University of Utah
Mary Playdon
Assistant Professor
University of Utah
Md Monowarul Mobin Siddique
Assistant Professor
University of Utah
Bing Li
Professor
The University of Iowa
Rebecca Seguin-Fowler
Associate Professor
Texas A&M University
Jared Rutter
Professor
University of Utah
Sheetal Hardikar
University of Utah
Liza Makowski
Professor
University of Tennessee Health Science Center
Dipayan Chaudhuri
University of Utah
Cynthia A. Thomson
-
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Xiaochen Zhang
Assistant Professor
Ohio State University
Katherine Cook
Associate Professor
Wake Forest University
Su Yon Jung
University of California, Los Angeles
William L. Holland
Associate Professor
University of Utah
juhua luo
Professor
Indiana University Bloomington School of Public Health
Kimberley Evason
Associate Professor
University of Utah
Michael B Wheeler
Professor
University of Toronto
E. Angela Murphy
Professor
Medical University of South Carolina
Patrice N Mimche
Associate Professor
Indiana University School of Medicine
Robin Shaw
Director
University of Utah
Yangbo Sun
Assistant Professor
University of Tennessee Health Science Center
marcia stefanick
Stanford University
Ting-Yuan Cheng
Associate Professor
Ohio State University
Nazmus Saquib
-
Make your next move.
Prepare your application
Review drafts before you send them.